{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T02:39:08Z","timestamp":1790995148024,"version":"4.1.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,3,27]],"date-time":"2024-03-27T00:00:00Z","timestamp":1711497600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,3,27]],"date-time":"2024-03-27T00:00:00Z","timestamp":1711497600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Atheroscler Rep"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1007\/s11883-024-01199-2","type":"journal-article","created":{"date-parts":[[2024,3,27]],"date-time":"2024-03-27T07:03:46Z","timestamp":1711523026000},"page":"147-152","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Oral PCSK9 Inhibitors"],"prefix":"10.1007","volume":"26","author":[{"given":"Anandita","family":"Agarwala","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramsha","family":"Asim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christie M.","family":"Ballantyne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,27]]},"reference":[{"issue":"2","key":"1199_CR1","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1038\/ng1509","volume":"37","author":"J Cohen","year":"2005","unstructured":"Cohen J, Pertsemlidis A, Kotowski IK, Graham R, Garcia CK, Hobbs HH. Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat Genet. 2005;37(2):161\u20135. https:\/\/doi.org\/10.1038\/ng1509.","journal-title":"Nat Genet"},{"issue":"2","key":"1199_CR2","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/ng1161","volume":"34","author":"M Abifadel","year":"2003","unstructured":"Abifadel M, Varret M, Rabes JP, Allard D, Ouguerram K, Devillers M, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet. 2003;34(2):154\u20136. https:\/\/doi.org\/10.1038\/ng1161.","journal-title":"Nat Genet"},{"issue":"18","key":"1199_CR3","doi-asserted-by":"publisher","first-page":"7100","DOI":"10.1073\/pnas.0402133101","volume":"101","author":"KN Maxwell","year":"2004","unstructured":"Maxwell KN, Breslow JL. Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype. Proc Natl Acad Sci U S A. 2004;101(18):7100\u20135. https:\/\/doi.org\/10.1073\/pnas.0402133101.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"12","key":"1199_CR4","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1056\/NEJMoa054013","volume":"354","author":"JC Cohen","year":"2006","unstructured":"Cohen JC, Boerwinkle E, Mosley TH Jr, Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med. 2006;354(12):1264\u201372. https:\/\/doi.org\/10.1056\/NEJMoa054013.","journal-title":"N Engl J Med"},{"issue":"18","key":"1199_CR5","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","volume":"376","author":"MS Sabatine","year":"2017","unstructured":"Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376(18):1713\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1615664.","journal-title":"N Engl J Med"},{"issue":"22","key":"1199_CR6","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","volume":"379","author":"GG Schwartz","year":"2018","unstructured":"Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018;379(22):2097\u2013107. https:\/\/doi.org\/10.1056\/NEJMoa1801174.","journal-title":"N Engl J Med"},{"issue":"16","key":"1199_CR7","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","volume":"382","author":"KK Ray","year":"2020","unstructured":"Ray KK, Wright RS, Kallend D, Koenig W, Leiter LA, Raal FJ, et al. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. N Engl J Med. 2020;382(16):1507\u201319. https:\/\/doi.org\/10.1056\/NEJMoa1912387.","journal-title":"N Engl J Med"},{"issue":"24","key":"1199_CR8","doi-asserted-by":"publisher","first-page":"2262","DOI":"10.1016\/j.jacc.2023.10.020","volume":"82","author":"CM Ballantyne","year":"2023","unstructured":"Ballantyne CM, Minhas AMK, Orringer CE. Inclisiran: where are we on safety, efficacy, and clinical effectiveness of siRNA therapies for prevention? J Am Coll Cardiol. 2023;82(24):2262\u20134. https:\/\/doi.org\/10.1016\/j.jacc.2023.10.020.","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"1199_CR9","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1161\/CIRCULATIONAHA.123.065407","volume":"148","author":"U Landmesser","year":"2023","unstructured":"\u2022 Landmesser U, Makhmudova U. New chapter in the PCSK9 book: oral inhibition of PCSK9 binding to the LDL receptor with a macrocyclic peptide. Circulation. 2023;148(2):159\u201361. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.123.065407. This editorial describes the challenges of developing orally bioavailable PCSK9 inhibitors.","journal-title":"Circulation"},{"issue":"2","key":"1199_CR10","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1161\/CIRCULATIONAHA.122.063372","volume":"148","author":"DG Johns","year":"2023","unstructured":"Johns DG, Campeau LC, Banka P, Bautmans A, Bueters T, Bianchi E, et al. Orally bioavailable macrocyclic peptide that inhibits binding of PCSK9 to the low density lipoprotein receptor. Circulation. 2023;148(2):144\u201358. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.122.063372.","journal-title":"Circulation"},{"issue":"22","key":"1199_CR11","doi-asserted-by":"publisher","first-page":"13796","DOI":"10.1021\/acs.jmedchem.0c01084","volume":"63","author":"C Alleyne","year":"2020","unstructured":"\u2022 Alleyne C, Amin RP, Bhatt B, Bianchi E, Blain JC, Boyer N, et al. Series of novel and highly potent cyclic peptide PCSK9 inhibitors derived from an mRNA display screen and optimized via structure-based design. J Med Chem. 2020;63(22):13796\u2013824. https:\/\/doi.org\/10.1021\/acs.jmedchem.0c01084. This article reports the iterative medical chemistry alterations and drug design enhancements involved in developing oral agents for PCSK9 inhibition.","journal-title":"J Med Chem"},{"issue":"22","key":"1199_CR12","doi-asserted-by":"publisher","first-page":"16770","DOI":"10.1021\/acs.jmedchem.1c01599","volume":"64","author":"TJ Tucker","year":"2021","unstructured":"Tucker TJ, Embrey MW, Alleyne C, Amin RP, Bass A, Bhatt B, et al. A series of novel, highly potent, and orally bioavailable next-generation tricyclic peptide PCSK9 inhibitors. J Med Chem. 2021;64(22):16770\u2013800. https:\/\/doi.org\/10.1021\/acs.jmedchem.1c01599.","journal-title":"J Med Chem"},{"key":"1199_CR13","unstructured":"ClinicalTrials.gov. A study of MK-0616 in participants with moderate renal impairment (MK-0616-007). 2023. https:\/\/clinicaltrials.gov\/study\/NCT05070390. Accessed 12 Oct 2023."},{"key":"1199_CR14","unstructured":"ClinicalTrials.gov. MK-0616 (Oral PCSK9 Inhibitor) renal impairment study 2 (MK-0616-020). 2023. https:\/\/clinicaltrials.gov\/study\/NCT05934292. Accessed 12 Oct 2023."},{"issue":"16","key":"1199_CR15","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1016\/j.jacc.2023.02.018","volume":"81","author":"CM Ballantyne","year":"2023","unstructured":"\u2022 Ballantyne CM, Banka P, Mendez G, Garcia R, Rosenstock J, Rodgers A, et al. Phase 2b randomized trial of the oral PCSK9 inhibitor MK-0616. J Am Coll Cardiol. 2023;81(16):1553\u201364. https:\/\/doi.org\/10.1016\/j.jacc.2023.02.018. This article reports significant, dose-dependent LDL-C reduction with good tolerability with the oral PCSK9 inhibitor MK-0616 in 381 patients with hypercholesterolemia.","journal-title":"J Am Coll Cardiol"},{"key":"1199_CR16","unstructured":"ClinicalTrials.gov. A research study looking at how NNC0385-0434 tablets work to lower blood cholesterol in people with heart disease or a high risk of heart disease. 2023. https:\/\/clinicaltrials.gov\/study\/NCT04992065. Accessed 13 Oct 2023."},{"key":"1199_CR17","unstructured":"ClinicalTrials.gov. A study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of AZD0780 in healthy subjects. 2023. https:\/\/clinicaltrials.gov\/study\/NCT05384262. Accessed 16 Oct 2023."},{"key":"1199_CR18","unstructured":"ClinicalTrials.gov. A study of MK-0616 (Oral PCSK9 Inhibitor) in adults with hypercholesterolemia (MK-0616-013): CORALreef lipids. 2023. https:\/\/clinicaltrials.gov\/study\/NCT05952856. Accessed 13 Oct 2023."},{"key":"1199_CR19","unstructured":"ClinicalTrials.gov. A study of MK-0616 (Oral PCSK9 Inhibitor) in adults with heterozygous familial hypercholesterolemia (MK-0616-017): CORALreef HeFH. 2023. https:\/\/clinicaltrials.gov\/study\/NCT05952869. Accessed 13 Oct 2023."},{"key":"1199_CR20","unstructured":"ClinicalTrials.gov. MK-0616 (Oral PCSK9 Inhibitor) cardiovascular outcomes study (MK-0616-015) CORALreef outcomes. 2023. https:\/\/clinicaltrials.gov\/study\/NCT06008756. Accessed 13 Oct 2023."},{"key":"1199_CR21","doi-asserted-by":"publisher","unstructured":"Gennemark P, Walter K, Clemmensen N, Rekic D, Nilsson CAM, Knochel J, et al. An oral antisense oligonucleotide for PCSK9 inhibition. Sci Transl Med. 2021;13(593). https:\/\/doi.org\/10.1126\/scitranslmed.abe9117.","DOI":"10.1126\/scitranslmed.abe9117"},{"issue":"1","key":"1199_CR22","doi-asserted-by":"publisher","first-page":"87","DOI":"10.33590\/emjcardiol\/10303462","volume":"11","author":"CE Kosmas","year":"2023","unstructured":"Kosmas CE, Papakonstantinou EJ, Carre\u00f1o J, EchavarriaUceta R, Guzman E, Sourlas A. PCSK9 targeting in the management of hypercholesterolaemia. EMJ Cardiol. 2023;11(1):87\u201397.\u00a0https:\/\/doi.org\/10.33590\/emjcardiol\/10303462.","journal-title":"EMJ Cardiol"},{"key":"1199_CR23","doi-asserted-by":"publisher","unstructured":"Koren MJ, Descamps O, Hata Y, Hengeveld EM, Hovingh GK, Ikonomidis I, et al. PCSK9 inhibition with orally administered NNC0385\u20130434 in hypercholesterolaemia: a randomised, double-blind, placebo-controlled and active-controlled phase 2 trial. Lancet Diabetes Endocrinol.\u00a02024;12(3):174\u2013183. https:\/\/doi.org\/10.1016\/S2213-8587(23)00325-X.","DOI":"10.1016\/S2213-8587(23)00325-X"},{"key":"1199_CR24","unstructured":"ClinicalTrials.gov. A study to assess the effect of AZD0780 on the pharmacokinetics of rosuvastatin. 2023. https:\/\/clinicaltrials.gov\/study\/NCT05787002. Accessed 16 Oct 2023."},{"key":"1199_CR25","unstructured":"ClinicalTrials.gov. An ADME study of [14C]AZD0780 in healthy male subjects. 2023. https:\/\/clinicaltrials.gov\/study\/NCT05817461. Accessed 16 Oct 2023."}],"container-title":["Current Atherosclerosis Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-024-01199-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11883-024-01199-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-024-01199-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T09:37:39Z","timestamp":1715333859000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11883-024-01199-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,27]]},"references-count":25,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["1199"],"URL":"https:\/\/doi.org\/10.1007\/s11883-024-01199-2","relation":{},"ISSN":["1523-3804","1534-6242"],"issn-type":[{"value":"1523-3804","type":"print"},{"value":"1534-6242","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,27]]},"assertion":[{"value":"13 March 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Ballantyne reports receiving consulting fees and research grants to his institution from Abbott Diagnostics, Akcea, Amgen, Arrowhead, Esperion, Ionis, Novartis, Novo Nordisk, Merck, Regeneron, and Roche Diagnostics. The other authors report that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}